Want to see AU:ADO full AI Analyst Report?
Top Page
AnteoTech Ltd
(Sydney:ADO)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.02
â–¼(-25.00% Downside)
Action:Upgraded
Date:09/06/26
The score is primarily constrained by weak financial performance—volatile and shrinking revenue in FY2026, continued large losses, and persistent negative operating/free cash flow—despite relatively modest leverage. Technicals add only limited support with generally weak momentum (low RSI, negative MACD) and no clear trend. Valuation is not compelling due to negative earnings (negative P/E) and no dividend yield provided.
Positive Factors
Multi-market technology platform
The platform addresses two distinct technology markets, diagnostics and energy storage, with applications designed to improve binding, stability, sensitivity, or electrochemical performance. This breadth can support multiple commercialisation pathways and reduce reliance on one end market.
Negative Factors
Sharp revenue contraction
The latest revenue decline raises concern about inconsistent commercial traction across the company’s target markets. A small and volatile revenue base makes fixed costs harder to absorb, limits operating leverage, and increases uncertainty around the timing of sustainable scale and recurring customer demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-market technology platform
The platform addresses two distinct technology markets, diagnostics and energy storage, with applications designed to improve binding, stability, sensitivity, or electrochemical performance. This breadth can support multiple commercialisation pathways and reduce reliance on one end market.
Read all positive factors
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$48.98M
Dividend YieldN/A
Average Volume (3M)6.74M
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue Growth-51.74%
EPS Growth24.00%
CountryAU
Employees224
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,265,153,800
10 Day Avg. Volume3,092,695
30 Day Avg. Volume6,744,405
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)6.74
Price to Sales (P/S)170.19
P/FCF Ratio-22.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$2.80M
AnteoTech Ltd Business Overview & Revenue Model
Company Description
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion ...
AnteoTech Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 467.59K | 968.88K | 460.40K | 365.72K | 760.88K |
| Gross Profit | -657.22K | 968.88K | 460.40K | 365.72K | 760.88K |
| EBITDA | -6.38M | -7.96M | -11.57M | -12.35M | -12.07M |
| Net Income | -4.93M | -6.76M | -8.88M | -12.65M | -10.72M |
Balance Sheet | |||||
| Total Assets | 15.40M | 6.45M | 9.38M | 5.36M | 15.26M |
| Cash, Cash Equivalents and Short-Term Investments | 11.20M | 2.34M | 5.03M | 2.72M | 10.10M |
| Total Debt | 2.15M | 1.96M | 2.31M | 1.31M | 1.03M |
| Total Liabilities | 3.60M | 3.30M | 4.08M | 2.99M | 2.91M |
| Stockholders Equity | 11.80M | 3.15M | 5.31M | 2.38M | 12.36M |
Cash Flow | |||||
| Free Cash Flow | -3.58M | -6.05M | -7.58M | -8.77M | -11.77M |
| Operating Cash Flow | -3.53M | -5.83M | -6.52M | -8.08M | -8.65M |
| Investing Cash Flow | -5.55M | -174.87K | -1.06M | -690.83K | -3.12M |
| Financing Cash Flow | 12.45M | 3.32M | 9.89M | 1.39M | 482.29K |
AnteoTech Ltd Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.02
Positive
Market Momentum
>-0.01
Negative
38.54
Neutral
166.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.54 is Neutral, neither overbought nor oversold. The STOCH value of 166.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ADO.
AnteoTech Ltd Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | AU$5.34B | 112.95 | 7.11% | ― | 26.66% | 179.32% | |
49 Neutral | AU$415.04M | -46.49 | -42.35% | ― | 145.32% | 25.75% | |
45 Neutral | AU$783.47M | -7.24 | -51.15% | ― | ― | -44.83% | |
44 Neutral | AU$48.98M | -14.17 | -71.28% | ― | -51.74% | 24.00% | |
43 Neutral | AU$22.33M | -2.23 | -129.15% | ― | -23.71% | -16.02% | |
42 Neutral | AU$28.27M | -0.38 | -144.24% | ― | -23.82% | 12.36% |
* Basic Materials Sector Average
AU:ADO
AnteoTech Ltd
0.02
>-0.01
-22.73%
AU:SPL
Starpharma Holdings Limited
0.80
0.47
147.66%
AU:TLX
Telix Pharmaceuticals
15.61
0.23
1.50%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.10
-2.10
-50.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.13
-0.23
-63.89%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-67.74%
AnteoTech Ltd Corporate Events
AnteoTech Publishes FY2026 Results and Schedules Investor Webinar
Sep 29, 2026
AnteoTech Ltd has released its full-year 2026 results and a business update presentation, which will be discussed in a live webinar hosted by Managing Director and CEO Merrill Gray. The session, scheduled for 30 September 2026, will be accessible ...
AnteoTech boosts cash reserves with $1.9m R&D tax rebate
Sep 29, 2026
AnteoTech Ltd has received a $1.9 million Research and Development Tax Incentive rebate from the Australian Taxation Office for the 2026 financial year. The rebate relates to eligible Australian RD activities across its Advanced Battery Technologi...
AnteoTech refreshes governance framework and diversity disclosures
Sep 27, 2026
AnteoTech has updated its corporate governance statement, reaffirming its alignment with the ASX Corporate Governance Council’s fourth edition principles and its adoption of a revised Corporate Governance Charter first implemented in late 20...
AnteoTech Issues New Tranche of Unquoted Employee Options
Sep 24, 2026
AnteoTech Ltd has disclosed the issuance of 8,758,000 unquoted options under its employee incentive scheme, with an exercise price of $0.0375 and an expiry date of 22 September 2030. The options, not intended to be quoted on the ASX, represent a c...
AnteoTech schedules FY26 investor briefing to outline growth plans
Sep 22, 2026
AnteoTech Ltd will host an investor webinar and conference call on 30 September 2026 to discuss its FY26 results, which are scheduled for release on 28 September 2026. Managing director and CEO Merrill Gray will brief investors on the company̵...
AnteoTech Sets November Date for 2026 Annual General Meeting
Sep 17, 2026
AnteoTech Ltd has scheduled its 2026 Annual General Meeting for 10:00 a.m. AEST on 10 November 2026 at Rydges South Bank in Brisbane, with director nominations closing on 25 September and detailed AGM materials to be released to the market by 9 Oc...
AnteoTech Issues Equity Incentive Shares Under Corporations Act Cleansing Notice
Sep 15, 2026
AnteoTech has issued 5,386,569 fully paid ordinary shares to staff as part of its FY2026 performance outcomes under the company’s Equity Incentive Plan. The shares were issued without a disclosure document under the provisions of section 708...
AnteoTech lifts FY2026 loss after non-cash lease adjustment
Sep 15, 2026
AnteoTech Ltd, an ASX-listed technology company based in Brisbane, focuses on advanced materials and diagnostics solutions for commercial and industrial markets, with investors closely tracking its capital position and adherence to financial repor...
AnteoTech Options Lapse, Streamlining Capital Structure
Sep 13, 2026
AnteoTech Ltd has notified the ASX of the cessation of 73,251,921 options, ADOAY, which expired on Sept. 13, 2026, without being exercised or converted. The lapse of these options reduces the pool of potential future share dilution, clarifying the...
AnteoTech CFO and Company Secretary Steps Down, Succession Process Begins
Sep 8, 2026
AnteoTech Limited has announced the resignation of Chief Financial Officer and Company Secretary Scott Waddell, who is leaving to pursue other business interests. The board has thanked Waddell for his contribution and will commence a search proces...
AnteoTech Issues Shares Under Short-Term Incentive Plan After KPI Review
Sep 1, 2026
AnteoTech has completed its FY2026 annual staff and executive performance review, concluding that 70.9% of company-wide KPIs were achieved in line with its ongoing commercialisation strategy. In recognition, the board approved the issuance of appr...
AnteoTech plans equity placement of 5.5 million new shares
Sep 1, 2026
AnteoTech Ltd has notified the Australian Securities Exchange of a proposed placement involving up to 5,544,884 ordinary fully paid shares. The company expects to issue the new securities on 15 September 2026, subject to ASX processes and listing ...
AnteoTech Narrows Loss as Cost Cuts and Fresh Capital Strengthen Balance Sheet
Aug 31, 2026
AnteoTech Ltd reported a narrower full-year loss of $4.93 million for the year to 30 June 2026, down 27% from the prior year, as cost reductions offset weaker operating revenue. Revenue from ordinary activities fell 52% to $0.47 million, though to...
AnteoTech Refreshes Securities Trading Policy to Bolster Governance
Aug 26, 2026
AnteoTech Limited has updated its Securities Trading Policy, effective 26 August 2026, signalling a refresh of its governance framework around share dealing by insiders. The revised policy, released to the market and made available on the company&...
AnteoTech triples life sciences sales pipeline after ADLM 2026
Aug 24, 2026
AnteoTech reported a significant expansion of its Life Sciences sales pipeline following its attendance at the ADLM 2026 diagnostics and laboratory medicine conference in Anaheim. The company engaged with diagnostic test and particle manufacturers...
AnteoTech Advances CLIA Collaboration and Prepares New Diagnostic Kit Launch
Jul 1, 2026
AnteoTech has completed the initial stage of a collaborative CLIA product development program, validating its AnteoBind NXT activated magnetic particles for use on large-scale automated diagnostic platforms and recognising A$61,595 in related reve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.